Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDTakeda Pharmaceutical Co Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$12.90 | -$11.22 | -$12.09 |
| Q2 2026 | 1 | $25.30 | $29.09 | $27.26 |
| Q3 2026 | 2 | $16.68 | $29.82 | $23.25 |
| Q4 2026 | 2 | $21.09 | $30.28 | $25.95 |
| Q1 2027 | 1 | -$11.81 | -$10.27 | -$11.07 |
| Q2 2027 | 1 | $32.14 | $36.95 | $34.63 |
| Q3 2027 | 1 | $76.27 | $87.70 | $82.19 |
| Q4 2027 | 1 | $61.61 | $70.83 | $66.38 |
| Q1 2028 | 1 | $46.45 | $53.41 | $50.05 |
Takeda Pharmaceutical Co Earnings Date And Information
Takeda Pharmaceutical Co last posted its earnings results on Thursday, July 30th, 2026. The company reported $0.225 earnings per share for the quarter, topping analysts' consensus estimates of $0.1689 by $0.0561. The company had revenue of 1,219.90 B for the quarter and had revenue of 4,777.45 B for the year. Takeda Pharmaceutical Co has generated $64 earnings per share over the last year ($63.91 diluted earnings per share) and currently has a price-to-earnings ratio of 48.5. Takeda Pharmaceutical Co has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Takeda Pharmaceutical Co Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 07/30/2026 | Q1 2026 | $0.17 | $35.83 | 35.66 | $1,151.75 B | $1,219.90 B |
| 05/26/2026 | Q4 2025 | N/A | -$7.92 | N/A | $1,143.39 B | $1,114.65 B |
| 01/29/2026 | Q3 2025 | $0.55 | $33.40 | 32.85 | $1,182.45 B | $1,213.21 B |
| 10/30/2025 | Q2 2025 | $0.44 | -$3.74 | -4.18 | $1,169.39 B | $1,112.80 B |
| 07/30/2025 | Q1 2025 | $0.47 | $39.70 | 39.23 | $1,156.79 B | $1,106.69 B |
| 06/25/2025 | Q4 2024 | N/A | -$32.62 | N/A | $1,100.48 B | $1,053.40 B |
| 12/31/2024 | Q3 2024 | N/A | $7.51 | N/A | $1,159.93 B | $1,144.12 B |
| 10/31/2024 | Q2 2024 | $0.39 | $29.07 | 28.68 | $1,063.99 B | $1,176.04 B |
| 06/28/2024 | Q1 2024 | N/A | $30.36 | N/A | $1,124.66 B | $1,207.99 B |
| 06/26/2024 | Q4 2023 | N/A | -$0.96 | N/A | $919.23 B | $1,050.87 B |
| 02/02/2024 | Q3 2023 | N/A | $33.69 | N/A | N/A | $1,111.19 B |
| 09/29/2023 | Q2 2023 | N/A | -$15.34 | N/A | N/A | $1,043.09 B |
| 06/29/2023 | Q1 2023 | N/A | $28.76 | N/A | N/A | $1,058.62 B |
| 03/30/2023 | Q4 2022 | N/A | $10.02 | N/A | N/A | $956.16 B |
| 12/30/2022 | Q3 2022 | N/A | $38.32 | N/A | N/A | $1,096.55 B |
| 09/29/2022 | Q2 2022 | N/A | $19.89 | N/A | N/A | $1,002.31 B |
| 06/29/2022 | Q1 2022 | N/A | $33.97 | N/A | N/A | $972.47 B |
| 03/30/2022 | Q4 2021 | N/A | -$3.65 | N/A | N/A | $873.29 B |
| 12/30/2021 | Q3 2021 | N/A | $18.45 | N/A | N/A | $901.29 B |
| 09/29/2021 | Q2 2021 | N/A | $14.62 | N/A | N/A | $844.82 B |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Takeda Pharmaceutical Co Earnings: FAQ's
In the previous quarter, Takeda Pharmaceutical Co (:TAK) reported $0.225 earnings per share (EPS) to beat the analysts' consensus estimate of $0.1689 by $0.0561.
The conference call for Takeda Pharmaceutical Co's latest earnings report can be listened to online.
The conference call transcript for Takeda Pharmaceutical Co's latest earnings report can be read online.
Takeda Pharmaceutical Co (:TAK) has a recorded annual revenue of $4,777.45 B.
Takeda Pharmaceutical Co (:TAK) has a recorded net income of $203.33 B.Takeda Pharmaceutical Co has generated $63.91 earnings per share over the last four quarters.
Takeda Pharmaceutical Co (:TAK) has a price-to-earnings ratio of 48.5 and price/earnings-to-growth ratio is 1.57.